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Abstract: Cartilage degradation frequently occurs during the postmenopausal period due to a decrease in type 2 collagen 
and constitutes a condition affected by the level of estrogen in the body. The purpose of this study is to prove that such post-
menopausal reductions in estrogen levels influence the type 2 collagen expression in cartilage. Oophorectomies were per-
formed on 54 Rattus norvegicus subjects and each of which was subsequently assigned to one of six different groups. 
17β-estradiol present in the blood of the subjects was examined by means of ELISA technique, while the expression of 
MMP-13 and type 2 collagen in their knee joint cartilage was assessed immunohistochemically. A significant post-oopho-
rectomy decrease of 17β-estradiol was detected in subjects (p<0.05), while the expression of MMP-13 increased apprecia-
bly (p<0.05) and a marked decrease in type 2 collagen expression occurred (p<0.05). The reduction in 17β-estradiol pro-
moted an increase in the expression of MMP-13 and a decrease in type 2 collagen expression.
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Introduction
Reduction in type 2 collagen is frequently encountered in postmeno-
pausal women suffering from osteoarthritis. Type 2 collagen is distribut-
ed across all layers of the cartilage, especially in the superficial layer. 
Therefore, a reduction in the level of type 2 collagen can be used as an 
indicator of joint cartilage degradation. Collagen creates mesh formation 
as a support for cartilage, enabling it to withstand tensile force, shearing 
force and compression force1). Studies have shown that reductions in 
blood estrogen levels reduce the cartilage collagen synthesis in joints2). 
In postmenopausal women, the level of estrogen in the blood is reduced, 
thereby affecting the synthesis of chondrocyte collagen. Epidemiologi-
cal studies conducted in Australia and the U.S.A. have indicated that os-
teoarthritis is more prevalent among postmenopausal women than in 
men3). However, the mechanism of type 2 collagen reduction related to 
this condition in postmenopausal women remains unclear.
Reports from various countries contained similar data indicating that 
women suffer to a greater extent from osteoarthritis than do men. In 
2015, the global prevalence of osteoarthritis among the people aged 
over 60-years-old stood at 9.6% for men, but the number is almost twice 
for women, at 18%. Australia reported that the total number of sufferers 
of the condition within its population amounted to 4 million. In 2016, 
the expenditure for the treatment of medical conditions related to osteo-
arthritis totaled US$ 5.5 billion. In 2013, 77 million Americans suffered 
from osteoarthritis, with a male to female ratio of 1:3, of which 10.5 
million (13.6%) requiring surgical intervention, including joint replace-
ment surgery, at a cost of US$ 6.35 billion per annum4).
Materials and Methods
Location
This study was conducted at the Experimental Animal Sustenance 
Unit, Pathology Laboratory, Faculty of Veterinary Medicine and at the 
Faculty of Science and Technology, Airlangga University on February – 
May 2018. This research was conducted in accordance to the procedures 
that are already authorized by the Research Ethics Commission, Faculty 
of Veterinary Medicine, Airlangga University, with authorisation Num-
ber 246/UN3.1.6/SP/2018 and Ethical Clearance Number 2.
KE.010.01.2018.
Study Subjects
This study was an experimental animal model study with Rand-
omized Post-Test Only Control Group design. Samples of this study was 
female Rattus norvegicus (Wistar strain), obtained from Experimental 
Animal Care Unit at Universitas Gajah Mada, Indonesia. The inclusion 
criteria were female rats aged 3 months with approximate weight of 200 
g and have never been pregnant. Exclusion criteria were sick rats during 
the samples recruitment. Drop-out criteria were infected rats after the 
Sham procedure or oophorectomy procedure. 
There were 6 groups in this study. Sample size of each group was 
calculated using Lemeshow formula and corrected with Higgins formula 
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to anticipate the drop-out5). Sample size needed for each group was 9 
rats, and the total samples for this study was 54 rats. At first, total sam-
ples were randomly divided into 2 groups, control group and interven-
tion group. After that, Sham procedure was done on the control groups, 
while the bilateral oophorectomy procedure was done on the interven-
tion groups. After the surgery, samples in control and intervention group 
randomly divided into 3 groups, namely C1, C2, and C3 group for the 
control group, and I1, I2, and I3 group for the intervention group. Sub-
jects in C1 and I1 group were observed for 4 weeks and then sacrificed, 
subjects in C2 and I2 group were observed for 8 weeks and then sacri-
ficed, subjects in C3 and I3 group were observed for 12 weeks and then 
sacrificed.
During sacrifice procedure, 2 cc of samples’ intra-cardiac blood was 
aspirated, and then the blood was centrifuged for 3-5 minutes with 
3,000x rotation per minute. The obtained serum was then used to evalu-
ate 17β-estradiol level using ELISA method (Rat Estrogen ELISA Kit, 
Cat.No E0176 Ra, Bioassay Technology Laboratory, Shanghai, China). 
Cartilage on the knee joint was also obtained during the sacrifice proce-
dure, and then preserved in the 10% formalin for immunohistochemistry 
evaluation of MMP-13 and type 2 collagen expression by using specific 
kit (Rabbit anti-Rat MMP-13 polyclonal and Rabbit anti-Rat Collagen 
Type 2 Polyclonal Antibody, BIOSS antibodies inc., Massachusetts, 
USA). 
ELISA Examination Procedure
The ELISA examination involved the following procedures. All rea-
gents, standard solutions and samples were prepared at room tempera-
ture. One hundred µl of standard solution was poured into a standard 
well and 100 µl of sample into a sample well, before adding 10 µl biotin 
conjugated anti E antibody. The diluted antibody was previously incu-
bated for 15-18 hours in 4°C temperature.  After that, 50 µl of streptavi-
din -HRP was added into the standard well prior to sealing it to prevent 
leakage and the well was incubated for 60 minutes at 37°C. The seal 
was opened and the plate was cleaned five times with a buffer before 
submerging it in 0.35 buffer solution for between 30-60 seconds. The 
plate was cleaned again five times with buffer solution and the area 
around the plate was cleaned with absorbent paper.
A and B substrate solution was added to each well and then the wells 
were incubated for ten minutes at 37°C until the color changed. Then 
the stop solution was added, and the result was read at 450 nm wave-
length. The OD (Optical Density) value was measured after 10 minutes. 
Immunohistochemical Staining
The histological specimen was deparaffinized and submerged in 
xylol solution four times for 3-5 minutes on each occasion in order to 
eradicate the endogenous peroxidase present. The specimen was then 
placed in absolute ethanol solution three times for 1-3 minutes, before 
being bathed twice in 70% ethanol for the same duration. It was subse-
quently washed three times using aqua bidestylata, while the slide bor-
der was cleaned with absorbent. Drops of hydrogen peroxide 3% were 
added before being incubated at room temperature for five minutes. The 
specimen was then washed three times with PBS 3 and the slide border 
cleaned. Drops of 0.025% trypsin were added and incubated at 37ᵒC for 
six minutes before cleaning was carried out three times with aquabides-
tyilata. In addition, the slide borders were cleaned. Drops of Ultra V 
Block were added and incubated at room temperature for five minutes. 
Drops of diluted monoclonal (1:100) were then added, incubated at 
room temperature for 25-30 minutes, prior to washing three times with 
PBS and cleaning of the slide border with absorbent was completed.
Drops of Primary Antibody Enhancer appropriate to the examination 
concerned were added and incubated at room temperature for ten min-
utes. After washing three times with PBS, drops of Horseradish Peroxi-
dase (HRP) polymer were added and incubated at room temperature for 
15 minutes. After washing three times with PBS, the slide border was 
cleaned.
Drops of the chromogen (20 µ/1 ml substrate) in accordance with 
the proposed examination were added and incubated at room tempera-
ture for 5-15 minutes in a darkened room, prior to washing three times 
with aquabidestylata and cleaning. Staining with Mayer’s hematoxylin 
solution, incubation at room temperature for 6-15 minutes and washing 
three times with running water was carried out, before bathing in water 
for ten minutes as the final cleaning. The results were dried and placed 
on a microscope object glass.
Statistical Analysis
All data acquired in this study was analyzed using SPSS Version 21. 
Shapiro-Wilk test was used to analyze the homogeneity of the data. 
Mann-Whitney test and Kruskall-Wallis test were used to analyze the 
difference in 17β-estradiol and type 2 collagen expression between 
groups. Brown-Forsythe test and Games-Howell test were used to ana-
lyze the difference in MMP-13 expression between groups.
Results
Table 1 shows the results of 17β-estradiol level measured by ELISA 
in the control and intervention groups. The estradiol level was decreased 
significantly in the intervention group compared to the control group 
(p<0.05). There was significant difference between C1 and I1 (p=0.015). 
There was significant difference between C2 and I2 (p=0.030) and be-
tween C3 and I3 (p=0.048), although there was no significant difference 
between the subgroups in the intervention group. The oophorectomy 
procedure resulted in a significant reduction in the level of estradiol.
Table 2 contains the results of MMP-13 expression using immuno-
histochemistry methods. It was found that MMP-13 expression in-
creased significantly in the intervention group (p<0.05), but there was 
no difference between the intervention subgroups (I1, I2, I3). There 
wasn’t significant difference between C1 and I1( p=0.107), but there 
was significant difference between C2 and I2 (p=0.012). There was sig-
nificant difference between C3 and I3 (p=0.002). It was concluded that 
oophorectomies cause increased MMP-13 levels in cartilage.
Table 3 shows the results of type 2 collagen expression using an im-
munohistochemical method. It was found that there was a significant 
decrease in type 2 collagen levels in the intervention group compared to 
the control group (p<0.05) due to the performing of oophorectomies. 
There was significant difference between C1 and I1 (p=0.002). There 
wasn’t significant difference between C2 and I2 (p=0.067) but there was 
significant difference C3 and I3 (p=0.004).
Discussion
Estrogen is synthesized mainly in the ovaries and adrenal gland. 
About 98-99% circulate around the body in a form bonded to the carrier 
protein, β-globulin, also referred as sex-hormone-binding globulin 
(SHBG). The remaining 1-2% of free or unbounded hormones can enter 
the target cell and bind with a specific receptor, inducing biological ef-
fect6).
Classic estrogen consists of estrone (E1), estradiol (E2) and estriol 
(E3). For women, 17β-estradiol is very important in maintaining the 
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physiologic function of reproductive organs, especially in the growth of 
follicles, and play an important role in sexual development. Known pe-
ripheral effects of this hormone are maintaining secondary sexual char-
acteristic; stimulation of hepatic protein synthesis such as renin substrate 
and globulin bound by sex hormone. The latest development showed 
that this hormone also maintains a good bone trabecular structure7).
The hormone 17β-estradiol is more potent than estrone, so the level 
of 17β-estradiol becomes a marker for menopause. Estrone only has 
1/50 of 17β-estradiol biological potential and estriol 1/80 of 17β-estra-
diol potential8).
Estrogen and hypophyseal gonadotrophic hormone stimulated the 
proliferation of granulous cells, mainly for follicular growth and oocyte 
development. The main effects of estrogen on genital tissue include: (1) 
inducing endometrial proliferation in the uterus, (2) influencing the pro-
duction of cervical secretion until it attains its maximum level at the 
mid-point of the menstrual cycle, and (3) maintaining the mucosal sur-
face of the vagina in a healthy condition by a process of vaginal epithe-
lium maturation6).
Extragenital effects including secondary sexual characteristic devel-
opment (estrogen constitutes the dominant stimulus in breast develop-
ment at the onset of puberty), induction of protein synthesis (Sex hor-
mone-binding globulin and renin substrate), maintenance of bone 
structure and prevention of osteoporosis. In menopausal women, the 
level of estradiol is frequently reduced leading to osteoporosis. This 
process is also thought to affect cartilage in osteoarthritic patients7).
Menopause represents the cessation of the menstrual cycle in women 
due to the reduction in the level of estrogen. The postmenopausal period 
is one commencing at the cessation of menstruation until 12 months lat-
er.
Estrogen plays a major role in the functioning of the genital organs, 
including: sexual differentiation and sexual/reproductive organ develop-
ment, in addition to exerting an extragenital effect on the endometrium, 
breast, non-joint bone and cartilage6). Estrogen also actively maintains 
the homeostasis of bone and cartilage, especially in postmenopausal os-
Table 1. Level of 17 β estradiol
Groups
Level of 17 β Estradiol (E2)
P
x SD Median Min Max
Control 4 weeks (C1) 9.888 1.596 9.833d 7.238 12.783
0.001*
Control 8 weeks (C2) 8.441 0.797 8.214c 7.264 10.05
Control 12 weeks (C3) 8.125 1.393 7.881bc 7.056 11.541
Intervention 4 weeks (I1) 7.976 1.104 7.529abc 6.354 9.802
Intervention 8 weeks (I2) 7.201 1.156 6.996ab 5.97 8.814
Intervention 12 weeks (I3) 6.848 0.922 7.058a 5.243 7.936
*p < 0.05 was considered statistically significant (Kruskall-wallis test)
Values in a column with different superscripts were significantly different (P < 0.05) from each other (Mann-whitney test)




x SD Min Max
Control 4 weeks (C1) 2.69ab 0.86 1.4 3.8
0.000*
Control 8 weeks (C2) 1.67a 1.06 0.4 3.6
Control 12 weeks (C3) 1.36a 1.02 0.2 3
Intervention 4 weeks (I1) 5.11b 2.3 2.8 8.6
Intervention 8 weeks (I2) 5.55b 2.24 3 10
Intervention 12 weeks (I3) 3.63b 0.81 2.6 5.2
*p < 0.05 was considered statistically significant (Brown-Forsythe test)
Values in a column with different superscripts were significantly different (P < 0.05) from each other (Games-Howell test)
Table 3. Expression of type 2 collagen 
Groups
Expression of Type 2 Collagen
P
x SD Median Min Max
Control 4 weeks (C1) 7.33 2.84 6.60c 3 11
0.000*
Control 8 weeks (C2) 5.04 3.29 4.80bc 1.4 12
Control 12 weeks (C3) 6.51 2.89 5.40b 2 11
Intervention 4 weeks (I1) 3.22 0.98 2.80ab 2 5.2
Intervention 8 weeks (I2) 2.55 1.25 2.50ab 0.6 4
Intervention 12 weeks (I3) 2.18 0.95 2.60a 0.6 3
*p < 0.05 was considered statistically significant (Kruskall-wallis test)
Values in a column with different superscripts were significantly different (P < 0.05) from each other (Mann-whitney test)
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teoarthritic women9). In experimental subjects, oophorectomies cause an 
increase in cartilage turnover and erosion of cartilage surfaces. Howev-
er, the mechanisms of this condition are still unclear10).
This study showed that there was a significant post-oophorectomy 
reduction in 17β- estradiol in the experimental subjects compared to that 
following the sham procedure (p<0.05). It also indicated an increase in 
MMP-13 expression in oophorectomized subjects compared to those 
undergoing the sham procedure (p<0.05). 
According to the study by Ito et al., estrogen could inhibit the TGF-β 
signaling pathway. In menopausal condition, in which estrogen level is 
decreased, the TGF-β signaling pathway would be disinhibited9). The ef-
fect of increasing TGF-β on chondroprogenitor cells is RUNX2 expres-
sion in the nuclei. An increase in hypertrophic chondrocyte cells is com-
monly caused by RUNX2 expression. As an intracrine, RUNX2 
stimulates differentiation towards chondrocyte hypertrophy6,11,12). Hyper-
trophic chondrocyte expresses several proteins, namely: alkaline phos-
phatase (ALP), vascular endothelial growth factor (VEGF), osteopontin, 
matrix metalloprotease 13 (MMP-13). The effect of increased MMP-13 
expression is the degradation of collagen, resulting in reduced expres-
sion of type 2 collagen in the joint cartilage of the subjects13). 
Several studies showed that administration of 17β-estradiol would 
decrease osteoclast activity by ERα activation, resulting in new bone 
formation and type-1 collagen synthesis. Moreover, estrogen or the re-
ceptor activation would upregulate osteoblast formation14). New bone 
formation would increase subchondral bone density which in turn will 
decrease the probability of OA. Another mechanism how estrogen may 
be protective to joint cartilage is by downregulation of inflammatory cy-
tokines. Estrogen inhibits the formation of pro-inflammatory cytokines 
such as IL-1β and TNF-α and modulate the expression of anti-inflam-
matory cytokine like IL-10, independent from the HPA axis15). The pro-
duction of MMP-13 is affected by said pro-inflammatory cytokines16). 
Thus, estrogen would decrease the expression of MMP-13, as demon-
strated by Claassen et al17). 
Turner et al. demonstrated that oophorectomies conducted on sheep 
had a significant effect on the aggregate modulus and shear modulus of 
articular cartilage, without any change to cartilage thickness6). Christgau 
et al. found post-oophorectomy increased cartilage degradation and de-
tected CTX II in mouse urine18). In postmenopausal women, there is an 
increase cartilage degradation and increased CTX II excretion in the 
urine which improved after the administering of levormeloxifene 
(SERM)18).
Andersen et al. found that oophorectomized rats had increased joint 
cartilage erosion/degradation due to estrogen depletion and the adminis-
tration of exogenous estrogen or SERM would inhibit the rate of degra-
dation10). However, it didn’t explain the exact mechanism of how estro-
gen depletion would lead to increased cartilage turnover as we aimed in 
our study. Our study found the similar result that oophorectomy would 
decrease the level of estrogen. The decrease of estrogen in turn would 
lead to increase the expression of MMP-13 which degrades the type 2 
collagen in the joint cartilage.
Cartilage is formed by chondrocytes and its extracellular matrix 
(ECM). Cartilage degradation will cause turnover type 2 collagen, be-
cause forms a collagen mesh which determines the strength of the carti-
lage16). The type 2 collagen content of  cartilage amounts to 90-95% 
with the result that its degradation will weaken the cartilage13).
There are 28 types of MMP contained in body tissue, but it is mainly 
MMP-13 which induces the cartilage to degrade type 2 collagen19). 
MMP-13 is also produced by the synovial cell, macrophage and chon-
drocytes influenced by IL-1 and TNF- α20). Number study showed that 
inflammation influenced IL-1 and TNF- α production and caused in-
creasing MMP- 1321).  This study showed that the decrease of 17β-estra-
diol resulted in elevated MMP-13 expression in cartilage (Table 2). 
MMP mechanism will induce enzymes to destroy organ matrix, includ-
ing oxidant, disulfide, alkylating agent, via a switching mechanism. In 
joint cartilage, this process is mainly due to oxidant activation which 
destroys collagen protein19). Therefore, 17β-estradiol affected type 2 col-
lagen levels in cartilage leading to an increased risk of osteoarthritis on 
postmenopausal women22).
The study by Asano et al. (2006) found that the production of MMP-
13 in the synovium is affected by levels inflammatory cytokines, IL-1 
and TNF-α. Thus, tissue inflammation would increase MMP-13 expres-
sion16). Our study showed that estrogen level depletion also increases 
MMP-13 expression trough hypertrophic chondrocyte formation. Fur-
ther study is needed to assess whether this phenomenon is primarily 
caused by inhibition of TGF-β pathway or by the anti-inflammatory ef-
fect of estrogen.
Other studies found that there is a correlation between muscle mass 
and the incidence of OA. Estrogen in the body keep the muscle mass in-
tact, and in post-menopause women, when the estrogen level is deplet-
ed, the muscle mass is reduced as well23, 24). However, in our study, we 
did not evaluate the effect of muscle mass. Further study needs to be 
done to determine the dominant factor of the OA, whether it is the mus-
cle mass or the increase in MMP-13 and decrease in collagen-type 2.
In conclusion the decrease in 17β-estradiol will decrease type 2 col-
lagen through the increase of MMP 13 on joint cartilage.
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